Proteins and Peptides

28 Jan 2021 PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress
24 Jan 2021 Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection
24 Jan 2021 FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
21 Jan 2021 Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
21 Jan 2021 INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
20 Jan 2021 Merck Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
10 Jan 2021 Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
07 Jan 2021 PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b to Treat Essential Thrombocythemia
06 Jan 2021 Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
06 Jan 2021 Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist
06 Jan 2021 AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)
05 Jan 2021 Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
05 Jan 2021 Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
05 Jan 2021 US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
30 Dec 2020 Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
29 Dec 2020 Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
29 Dec 2020 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
23 Dec 2020 Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
23 Dec 2020 ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
22 Dec 2020 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
22 Dec 2020 The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
18 Dec 2020 Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
18 Dec 2020 Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
18 Dec 2020 Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
18 Dec 2020 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top